The incidence and management of infusion reactions to infliximab: a large center experience
作者： Adam Cheifetz , Michelle Smedley , Sara Martin , Monica Reiter , Grace Leone
DOI: 10.1111/J.1572-0241.2003.07457.X
关键词:
摘要: The Incidence and Management of Infusion Reactions to Infliximab: A Large Center Experience
nature.com
sci-hub.se 参考文章(9)
Gordon L. Sussman, Kathleen Davis, Peter F. Kohler, Penicillin allergy: a practical approach to management Canadian Medical Association Journal. ,vol. 134, pp. 1353- 1356 ,(1986)
Thomas C. Puchner, Subra Kugathasan, Kevin J. Kelly, David G. Binion, Successful desensitization and therapeutic use of infliximab in adult and pediatric Crohn's disease patients with prior anaphylactic reaction. Inflammatory Bowel Diseases. ,vol. 7, pp. 34- 37 ,(2001) , 10.1097/00054725-200102000-00005
Paul Rutgeerts, Geert D'Haens, Stephan Targan, Eric Vasiliauskas, Stephen B. Hanauer, Daniel H. Present, Lloyd Mayer, Ruud A. Van Hogezand, Tanja Braakman, Kimberly L. DeWoody, Thomas F. Schaible, Sander J.H. Van Deventer, Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology. ,vol. 117, pp. 761- 769 ,(1999) , 10.1016/S0016-5085(99)70332-X
Kia Saeian, Subra Kugathasan, Sotirios Vasilopoulos, Jeanne Emmons, Kevin Joseph Kelly, Devang Prajapati, Joseph P. Kim, David G. Binion, Alfonso Martinez, Michael B. Levy, Infliximab retreatment in adults and children with Crohn’s disease: risk factors for the development of delayed severe systemic reaction The American Journal of Gastroenterology. ,vol. 97, pp. 1408- 1414 ,(2002) , 10.1016/S0002-9270(02)04140-0
Thomas Eppinger, Kirk Sperber, Desensitization to 5-fluorouracil. Allergy and Asthma Proceedings. ,vol. 20, pp. 189- 191 ,(1999) , 10.2500/108854199778553064
Stephen B Hanauer, Brian G Feagan, Gary R Lichtenstein, Lloyd F Mayer, S Schreiber, Jean Frederic Colombel, Daniel Rachmilewitz, Douglas C Wolf, Allan Olson, Weihang Bao, Paul Rutgeerts, Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial The Lancet. ,vol. 359, pp. 1541- 1549 ,(2002) , 10.1016/S0140-6736(02)08512-4
Stephan R. Targan, Stephen B. Hanauer, Sander J.H. van Deventer, Lloyd Mayer, Daniel H. Present, Tanja Braakman, Kimberly L. DeWoody, Thomas F. Schaible, Paul J. Rutgeerts, A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. The New England Journal of Medicine. ,vol. 337, pp. 1029- 1035 ,(1997) , 10.1056/NEJM199710093371502
Daniel H. Present, Paul Rutgeerts, Stephan Targan, Stephen B. Hanauer, Lloyd Mayer, R.A. van Hogezand, Daniel K. Podolsky, Bruce E. Sands, Tanja Braakman, Kimberly L. DeWoody, Thomas F. Schaible, Sander J.H. van Deventer, Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease New England Journal of Medicine. ,vol. 340, pp. 1398- 1405 ,(1999) , 10.1056/NEJM199905063401804
Thomas F Schaible, Long Term Safety of Infliximab Canadian Journal of Gastroenterology & Hepatology. ,vol. 14, ,(2000) , 10.1155/2000/698523